Hypertension drugs recalled by Dr Reddy's Laboratories

Published On 2015-09-05 07:05 GMT | Update On 2023-10-19 12:02 GMT

Dr Reddy's Laboratories will recall over 55,000 bottles of Amlodipine besylate and Atorvastatin calcium tablets, used to treat high blood pressure and cholesterol related diseases in the US

Dr Reddy's Laboratories is reported to have initiated a massive recall operation in the US market, as confirmed the USFDA; recalling over 55,000 bottles of its Amlodipine besylate and Atorvastatin calcium tablets. These drugs are primarily used for patients with high cholesterol and certain other conditions like high blood pressure, heart blood vessel problems and chest pain.

As per the USFDA, the company is recalling Amlodipine besylate and Atorvastatin calcium tablets in various strengths including 2.5mg/10mg, 2.5 mg/20 mg and 10mg /80 in 30 and 90 count bottles.

According to the US Food and Drug Administration (USFDA), Dr Reddy's Laboratories, Inc, the US-based arm of Hyderabad-based firm is recalling the drug for being "sub-potent".

The tablets being recalled by the company have been manufactured at its Bachupally facility, near Hyderabad and distributed in the US by its subsidiary, Dr Reddy's Laboratories, Inc.

The recall was initiated by the company on August 13 this year.

The recall of the drugs has been initiated under Class-III which FDA defined as "a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences".

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Hypertension drugs recalled by Dr Reddy's Laboratories

Similar News

'Indians are bad': Florida patient attacks Indian-origin nurse, breaks almost every bone on her face

Frailty tied to Adverse Events in RA Patients on Biologic and Targeted Synthetic DMARDs, finds study

High dietary acid load can potentially worsen cardiometabolic risk factors, study reveals

Diabetes stigma tied to food insecurity, disordered eating and lower psychosocial well-being in diabetes patients: Study

Physical Activity may ease symptom burden of postconcussion in children, suggests study

Strength training improves knee health, lowers risk of knee osteoarthritis: Study

Sibling death in childhood tied to increased risk of early-onset cardiovascular disease: JAMA

Bisoprolol safe and effective for treating chronic obstructive pulmonary disease: Study